A 61-year-old woman presents with a 3-year history of discomfort in the right thigh on exertion. Her symptoms have recently progressed to involve the right calf. She is able to walk no more than 50 m before having to stop because of leg pain. Her medical history is notable for coronary-artery bypass surgery after a myocardial infarction at 55 years of age and for hyperlipidemia, for which she takes atorvastatin at a dose of 40 mg daily. She has a smoking history of 50 pack-years and currently smokes eight cigarettes per day. On examination, the blood pressure is 126/82 mm Hg, there is a bruit over the right femoral artery, and pulses are diminished in the right leg. How would you evaluate and manage this case?
T he term "peripheral artery disease" classically encompasses the various diseases that affect noncardiac, nonintracranial arteries. The most common cause of peripheral artery disease is atherosclerosis; less common causes include inflammatory disorders of the arterial wall (vasculitis) and nonin flammatory arteriopathies, such as fibromuscular dysplasia. This review focuses on the management of stable peripheral artery disease that is due to atherosclero sis affecting the infrarenal aorta and the arteries of the legs. There are two broad subtypes of peripheral artery disease: proximal disease, which involves the aorto iliac and femoropopliteal locations, and distal disease, which involves the infra popliteal location.
1 Distal disease may be accompanied by calcification of the medial layer, which leads to poorly compressible arteries and is associated with high mortality. 2 On the basis of the prevalence in cohort studies of an abnormal ankle-bra chial index -the ratio of the systolic blood pressure at the ankle to the systolic blood pressure in the arm 3 -it is estimated that at least 8.5 million persons in the United States 4 and more than 200 million people worldwide 5 have peripheral artery disease. The total annual costs associated with the hospitalization of pa tients with peripheral artery disease in the United States are estimated to be in excess of $21 billion, 6 a number that is projected to rise as the population ages. The risk factors for peripheral artery disease are similar to those for other atherosclerotic vascular diseases, with smoking and diabetes mellitus being the strongest. 5 Markers of inflammation and thrombosis, elevated lipoprotein(a) and homocysteine levels, and chronic kidney disease are also associated with periph eral artery disease. 7 The prevalence of peripheral artery disease is similar among men and postmenopausal women, but men are more likely than women to have classic symp toms of claudication. Blacks have a lower anklebrachial index than whites, 8 even after adjustment for differences in risk factors. This difference may be due to physiologic factors, since it is also present among younger persons without cardio vascular risk factors. 9 Studies involving twins suggest that heritable factors confer a predispo sition to peripheral artery disease, 10 and in a case-control study, 11 a family history of periph eral artery disease was associated with a dou bling of the odds of the disease. However, rela tively few genetic variants that influence the susceptibility to peripheral artery disease have been discovered -in contrast to coronary heart disease, for which multiple genetic variants have been found -possibly because of greater clini cal and genetic heterogeneity in peripheral ar tery disease than in coronary heart disease.
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Peripheral artery disease is associated with several comorbid conditions; coronary heart dis ease, cerebrovascular disease, or both are pres ent in more than half the persons who receive a diagnosis of peripheral artery disease. 13 On the basis of registry data, the 1year incidence of cardiovascular death, myocardial infarction, and ischemic stroke was higher among persons with peripheral artery disease than among those with coronary heart disease (5.35% vs. 4.52%)
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; the incidence of adverse limb outcomes, including worsening of symptoms, the need for peripheral revascularization, and amputation, was 26% over a period of 4 years. 15 An ankle-brachial index of 0.9 or less is associated with more than twice the mortality that is associated with an ankle-brachial index of 1.11 to 1.40. 16 In spite of high morbidity and mortality, patients with pe ripheral artery disease are often underdiagnosed and undertreated.
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S tr ategies a nd E v idence
Assessment
Screening
The U.S. Preventive Services Task Force does not recommend routine screening with ankle-brachial indexes because of a lack of evidence that early detection results in more effective treatment of risk factors or better outcomes.
18 Targeted screening of persons who are at increased risk, such as persons who are older than 65 years of age and those who are older than 50 years of age and are smokers or have diabetes, is recom mended by the guidelines of the American Col lege of Cardiology and the American Heart As sociation (ACC-AHA).
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Symptoms and Signs at Presentation
Patients with peripheral artery disease may be asymptomatic, may have classic symptoms of claudication (discomfort on exertion in the muscle groups that are distal to the affected artery), or may have leg discomfort that is atypi cal for claudication. 21 A subgroup of patients may present with acute or chronic critical limb ischemia. Signs of peripheral artery disease in clude diminished pulses, arterial bruits, de creased capillary refill, pallor on elevation, and trophic changes. 21 Patients with critical limb ischemia often have pain at rest and ulceration or gangrene of the toes on examination. Shown are the results of measurement of segmental blood pressures and indexes in the leg and continuous-wave Doppler examination of the patient discussed in the vignette. To obtain segmental blood pressures, cuffs are placed at three or four sites on the legs. The higher of the two arm pressures is used to calculate each segment-brachial index (the ratio of the systolic blood pressure at the segment to the systolic blood pressure in the arm). Peripheral artery disease is considered to be present when the resting ankle-brachial index is 0.90 or less. Generally a drop in the blood pressure of more than 20 mm Hg between two adjacent locations indicates a hemodynamically significant stenosis. Continuous-wave Doppler waveforms can be qualitatively analyzed to assess arterial blood flow (circles indicate sites of Doppler-probe placement). Normally, a triphasic or biphasic response is present, whereas a reduced biphasic or monophasic signal indicates a hemodynamically significant stenosis. DP denotes dorsalis pedis, L left, PT posterior tibial, and R right. 19, 20 Computed tomography (CT) or magnetic resonance angiography may also be useful in planning for revascularization. CT angiography is widely available, requires a rela tively short scanning time, and provides high resolution images that can be processed for three dimensional reconstruction. Drawbacks are that it requires the use of vascular contrast material and may provide poor delineation of heavily calci fied or small distal vessels. Magnetic resonance angiography avoids the use of radiation and provides good spatial resolution but is techni cally more challenging than CT angiography, cannot be used in patients who have certain metallic or electronic implants, and carries a risk of nephrogenic systemic fibrosis when gadolinium that is used for the vascular contrast material is administered to patients with chron ic kidney disease.
Overview of Management
The main goals in treating patients with periph eral artery disease are to reduce the risks of ad verse cardiovascular outcomes, improve func tional capacity, and preserve limb viability (Fig. 2) . Multiple coexisting conditions are com mon in patients with peripheral artery disease and present additional challenges in treatment.
Treatment of Cardiovascular Risk Factors
Hyperlipidemia
Recent guidelines recommend highintensity statin therapy in patients with atherosclerotic vascular disease to lower the lowdensity lipo protein (LDL) cholesterol level by 50% or more, but the guidelines do not mandate a specific target level of LDL cholesterol. 22 In the Heart Protection Study, 23 the subgroup of patients with peripheral artery disease who were assigned to simvastatin had a reduction of 25% relative to the reduction among those assigned to placebo, in the risk of cardiovascular events over 5 years of followup -a reduction that was similar to that observed in the subgroup of patients with out peripheral artery disease. In a large registry study, patients with peripheral artery disease who were taking statins had a rate of adverse limb outcomes (including worsening of symptoms, the need for peripheral revascularization, and ampu tation) that was 18% lower than the rate among patients who were not taking statins.
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Hypertension
There is controversy with regard to bloodpres sure targets, with a recent trial suggesting that the systolic bloodpressure goal should be less than 120 mm Hg in patients at high cardiovas cular risk. 24 There are no comparative trials to support the use of one particular class of anti hypertensive agent over another in patients with peripheral artery disease. However, angiotensin converting-enzyme inhibitors may be preferred agents to reduce the risk of adverse cardiovascu lar events in peripheral artery disease. 19, 20 In the Heart Outcomes Prevention Evaluation Study 25 , which involved 9297 patients with diabetes or vascular disease (including 4051 patients with peripheral artery disease), treatment with ramipril resulted in a lower risk of adverse cardiovascu lar outcomes than the risk with placebo, over 5 years of followup. When indicated, beta blockers can be safely used in patients with pe ripheral artery disease.
Diabetes
The treatment of diabetes does not reduce the risk of cardiovascular events but may lower the The ankle-brachial index (ABI) is the ratio of the systolic blood pressure at the ankle to the systolic blood pressure in the arm. This observation is relevant to patients with pe ripheral artery disease and diabetes, in whom foot ulceration is a debilitating adverse outcome. Since intensive bloodglucose control may in crease mortality among patients with estab lished cardiovascular disease, 27 a target glycated hemoglobin level should be chosen on the basis of the age of the patient, the duration of diabe tes, and the presence of coexisting conditions. Proper foot care, daily inspection of the feet, and prompt evaluation of any skin lesion or ulcer ation are recommended.
Smoking Cessation
Persons with peripheral artery disease who stop smoking have a lower risk of death, progression of disease, critical limb ischemia and amputa tion, myocardial infarction, stroke, and bypass graft failure than those who continue to smoke.
28
Referral for counseling, the use of adjunctive pharmacotherapy (varenicline, bupropion, or nicotinereplacement therapy), or both may in crease abstinence rates.
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Antiplatelet Agents
Patients with symptomatic peripheral artery dis ease should receive antiplatelet therapy in the form of aspirin (at a dose of 75 to 325 mg daily). A metaanalysis of randomized trials of aspirin use in patients with peripheral artery disease showed no significant reduction in the risk of cardiovascular events but a significant reduc tion in the risk of nonfatal stroke. 29 Aspirin did not improve outcomes among persons with an ankle-brachial index of 0.95 or less who did not have symptoms. 30 In a randomized trial that included persons with symptomatic periph eral artery disease or other manifestations of atherosclerotic vascular disease, clopidogrel (at a dose of 75 mg daily) was slightly more effective than aspirin in reducing the risk of a composite outcome of ischemic stroke, myocardial infarc tion, or death from vascular causes.
31 Dual anti platelet therapy can be considered in patients with symptomatic peripheral artery disease who are not at increased risk for bleeding.
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Vorapaxar, a new antiplatelet agent that blocks the thrombin proteaseactivated receptor 1, reduced the risk of cardiovascular death or ischemic events among patients with atheroscle rotic vascular disease but increased the risk of bleeding events, including intracranial hemor rhage. 33 In the subgroup of patients with periph eral artery disease, the drug reduced the risk of acute limb ischemia and peripheralrevascular ization events, 34 which led to its approval for use in patients with peripheral artery disease who did not have a history of stroke. Warfarin is not recommended, because the combination of war farin and aspirin did not result in a greater re duction in the risk of cardiovascular events than aspirin alone and was associated with more bleeding.
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Improving Functional Capacity
Overview
The association between the ankle-brachial index and functional capacity in patients with peripheral artery disease is modest, and poor functional capacity in patients with peripheral artery disease is often multifactorial, including conditions such as coronary heart disease, pul monary disease, and degenerative joint disease.
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Several strategies may improve functional capac ity in patients with peripheral artery disease.
Supervised Exercise
A program that incorporates walking at least three times per week (30 to 60 minutes per ses sion) for at least 12 weeks should be the first line therapy for claudication. In a trial compar ing supervised exercise with stenting in patients with aortoiliac disease who were receiving med ical therapy, supervised exercise resulted in sig nificantly greater mean peak walking time at 6 months (5.8 vs. 3.7 minutes) 37 ; however, quality oflife indicators were better in the patients who were randomly assigned to stenting. Supervised exercise for peripheral artery disease is not reim bursed by insurers in the United States. A home based, groupmediated, cognitive behavioral walk ing intervention that included goal setting, selfmonitoring, managing pain during exercise, and walking at least 5 days per week lengthened the 6minute walking distance by 53 m over the distance walked by the control group that re ceived health education alone. the maximal walking distance on a treadmill by approximately 25%, as compared with placebo.
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Side effects include tachycardia, diarrhea, and increased bleeding tendency; it is contraindicat ed in patients with heart failure or low ejection fraction. Nafronyl, a 5hydroxytryptamine-recep tor blocker that inhibits platelet aggregation, may be more effective than cilostazol and is approved in Europe for claudication. 39 Atorvas tatin (at a dose of 80 mg daily for 12 months) was associated with a modestly longer painfree walking time, but not a longer maximal walking time, than was placebo.
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Revascularization
Revascularization is indicated when there are limiting symptoms in spite of an exercise pro gram and medical therapy and there is a reason able likelihood that symptoms can be reduced (including absence of other conditions that might limit functional capacity, such as heart failure or lung disease); it is also indicated for limb salvage in the context of critical limb is chemia. Commonly performed revascularization procedures for peripheral artery disease are shown in Figure 3 and Figure S2 in the Supple mentary Appendix. An individualized approach should be adopted to select a revascularization strategy for each patient on the basis of the pa tient's preferences, anatomical factors, the avail ability of appropriate conduits, and operative risk. Supervised exercise may serve as a useful adjunct to revascularization. In a trial involving 212 patients with claudication, those who were randomly assigned to endovascular revascular ization and supervised exercise had a longer maximal walking distance at 12 months than did those who were randomly assigned to exer cise alone (1237 vs. 955 m).
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Aortoiliac angioplasty and stenting (Fig. S1 in the Supplementary Appendix) have high proce dural success rates (approximately 96%) and a 3year patency rate of approximately 82%.
42 Stent placement is generally avoided in the common femoral artery, owing to the risk of biomechani cal stressrelated stent fractures and the poten tial for interference with future arterial access. Endovascular intervention in the superficial femoral artery is associated with high rates of restenosis, and several technologies to limit restenosis, including drugeluting or covered stents and drugcoated balloons, are being eval uated (Fig. 3) . Endovascular therapy of isolated infrapopliteal disease is not recommended for claudication. 19, 20 Patients should receive dual antiplatelet therapy for at least 30 days or for a longer period if a drugeluting stent is placed. 43 Surgical bypass (Fig. S2 in the Supplementary Appendix) should be considered when an endo vascular approach has failed or is not feasible from an anatomical standpoint. Aortofemoral bypass is a durable operation for aortoiliac dis ease, with patency rates up to 90% at 5 years.
44
In patients who are poor candidates for surgery, crossclamping of the aorta can be avoided by an axillary-femoral graft, which is often combined with a femoral-femoral graft. Endarterectomy is the procedure of choice for common femoral artery lesions and is often combined with an en dovascular approach. The saphenous vein is the preferred conduit for infrainguinal bypass, but a prosthetic conduit can be used for femoral-pop liteal bypass if the aboveknee popliteal artery is the target vessel and good runoff is present.
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Femoral-tibial bypass is an option in patients with critical limb ischemia and infrapopliteal disease.
There is no clear guidance regarding anti thrombotic therapy after surgical revasculariza tion; however, in patients undergoing infra inguinal bypass surgery, venous grafts had better patency with warfarin than with aspirin therapy, whereas prosthetic grafts had better patency with aspirin. 46 For belowknee pros thetic grafts, dual antiplatelet therapy is pre ferred. A cardiac stress imaging study may be indicated preoperatively to assess the presence and severity of coronary heart disease in patients with peripheral artery disease who have poor functional capacity. 47 However, there is no benefit from prophylactic coronary revascularization in patients with peripheral artery disease who are undergoing surgical revascularization. Balloon angioplasty, stenting (with balloon-expandable or self-expanding stents), and atherectomy are common endovascular procedures. Drug-eluting or covered stents and drug-coated balloons are being evaluated to reduce the rate of restenosis.
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Randomized trials are needed to compare medi cal therapy and supervised exercise with revascu larization and to compare endovascular revas cularization with surgical revascularization, particularly in patients with distal (infrapopli teal) peripheral artery disease. Studies are also needed to inform appropriate treatment of pa tients with peripheral artery disease who are asymptomatic, have concomitant disease in oth er arterial beds, or have poorly compressible ar teries owing to calcification of the medial layer. The role of new antiplatelet or anticoagulant drugs in reducing cardiovascular risk among patients with peripheral artery disease is being assessed in ongoing trials (ClinicalTrials.gov numbers, NCT01732822 and NCT01776424). Ad ditional data are also needed to guide anti thrombotic therapy after revascularization. Mo lecular and regenerative medicine therapies for severe peripheral artery disease are being inves tigated.
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Guidelines
The ACC-AHA published updated guidelines for the management of peripheral artery disease in 2011. 20 The TransAtlantic InterSociety, 42 which represents 16 professional societies from several countries, the Society for Vascular Surgery, 45 and the European Society of Cardiology 50 have also published guidelines for the management of peripheral artery disease. The recommendations in this article are generally concordant with these guidelines.
Conclusions a nd R ecommendations
The patient described in the vignette has symp toms consistent with claudication. She should undergo a noninvasive arterial evaluation. An ankle-brachial index of 0.9 or less would be consistent with peripheral artery disease, and continuouswave Doppler waveform analysis and measurement of segmental blood pressures are useful to identify the location of disease. She should be counseled regarding smoking cessa tion and should start a supervised or a home based exercise program. We would initiate cilo stazol at a dose of 100 mg twice daily and consider increasing the dose of atorvastatin to 80 mg daily. If her symptoms continued to limit her activity despite these interventions, we would recommend angiography and revascularization. An endovascular approach would be considered for proximal disease, whereas surgical revascu larization would be considered for distal (infrap opliteal) disease.
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